Key Insights

Highlights

Success Rate

67% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 54/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.8% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results67% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 3 (2)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.5%

Based on 2 completed trials

Clinical Trials (3)

Research Network

Activity Timeline